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Abstract
Background: Several metrics of glucose variability have been proposed to date, but an integrated approach that
provides a complete and consistent assessment of glycemic variation is missing. As a consequence, and because
of the tedious coding necessary during quantification, most investigators and clinicians have not yet adopted the
use of multiple glucose variability metrics to evaluate glycemic variation.
Methods: We compiled the most extensively used statistical techniques and glucose variability metrics, with
adjustable hyper- and hypoglycemic limits and metric parameters, to create a user-friendly Continuous Glucose
Monitoring Graphical User Interface for Diabetes Evaluation (CGM-GUIDEª). In addition, we introduce and
demonstrate a novel transition density profile that emphasizes the dynamics of transitions between defined
glucose states.
Results: Our combined dashboard of numerical statistics and graphical plots support the task of providing an
integrated approach to describing glycemic variability. We integrated existing metrics, such as SD, area under
the curve, and mean amplitude of glycemic excursion, with novel metrics such as the slopes across critical
transitions and the transition density profile to assess the severity and frequency of glucose transitions per day as
they move between critical glycemic zones.
Conclusions: By presenting the above-mentioned metrics and graphics in a concise aggregate format, CGM-
GUIDE provides an easy to use tool to compare quantitative measures of glucose variability. This tool can be
used by researchers and clinicians to develop new algorithms of insulin delivery for patients with diabetes and
to better explore the link between glucose variability and chronic diabetes complications.
Introduction
As the use of continuous glucose monitors becomesmore prevalent in the management of type 1 diabetes
mellitus (T1DM), metrics for interpreting and connecting con-
tinuous glucose monitoring (CGM) data to therapeutic algo-
rithms of insulin delivery are essential for themost effective use
of continuous glucose monitors in clinical care, with the ulti-
mate goal of preventing chronic diabetes complications in-
cluding nephropathy and kidney failure, retinopathy and
blindness, peripheral neuropathy, and cardiovascular disease.
Glucose variability is under consideration as a possible link to
diabetes complications, with studies reporting its role in pro-
moting increased oxidative stress1 and vascular pathology.2,3
Currently, the statistics and metrics used to reflect glucose
dynamics include, but are not limited to, the overall SD from a
mean glucose value, percentage of values within, above, or
below specified thresholds, area under the curve, mean am-
plitude of glycemic excursion (MAGE),4 mean of daily differ-
ences (MODD),5 and continuous overall net glycemic action
(CONGA) (for the indicated n hours).6 Additional metrics in-
clude the M-value,7 average daily risk range,8 Glycemic Risk
Assessment Diabetes Equation scores,9 and J-index.10 Incon-
sistencies, however, can arise from the miscalculation, misin-
terpretation, and misuse of these metrics in disparate data
types and applications.
Of primary concern is the practical implementation of rig-
orous glucose variability metrics and glycemic statistics in the
clinic, where there is currently a lack of software that provides
easy quantification and comparison of glucose variability
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data. Here we provide a standardized approach for visual-
izing the dynamics associated with crossing into different
regions of glycemia through the development of a novel his-
togram plot—from here onward referred to as the ‘‘transition
density profile’’—that assesses the severity and frequency of
glucose transitions per day as they move between critical
glycemic zones. Also, to address the translational gap be-
tween existing metrics and their actual use in clinical practice,
we have created the Continuous Glucose Monitoring Graph-
ical User Interface for Diabetes Evaluation (CGM-GUIDEª) to
integrate the evaluation of CGM data.
Materials and Methods
CGM data were provided by the laboratory of R.P.-B. and
were collected on an iPro CGM system (Medtronic, North-
ridge, CA) in adult patients with T1DM under normal daily
conditions for up to 5 days. The study was approved by the
Institutional Review Board at the University of Michigan (Ann
Arbor), and all subjects signed a written informed consent.
Here we present detailed analysis from four subjects with
T1DM to appreciate the full functionality of CGM-GUIDE.
Reference metric values for those without diabetes were re-
ported in independent studies by McDonnell et al.,6 based on
CGM traces for 10 healthy controls without diabetes, by
Cameron et al.,11 based on CGM traces for 12 healthy controls
without diabetes, and Fox et al.12 based on CGM traces for 74
healthy controls without diabetes (Table 1). Each patient’s in-
terstitial glucose levels (from here forward referred to as
‘‘glucose’’) were sampled at 5-min intervals for up to 140h.
CGM-GUIDE was designed using Matlab version 2008b (The
MathWorks, Natick, MA) with descriptions of user inputs and
novel CGM-GUIDE outputs, including transition speeds
and the transition density profile, as well as standard statis-
tics and metrics. Gaps or null data points are automatically
deleted and not included in the calculated times or areas.
Definitions
Time interval. Time interval (in min) is the interval at
which the CGM glucose data were collected.
Bin thresholds. The bounding threshold values (in mg/
dL) are those into which raw CGM data will be binned, such
that Bin(1) contains all raw values that satisfy the condition
[threshold(1) < glucose£ threshold(2)] (Fig. 1).
Hyperglycemic/hypoglycemic limit. All glucose values
greater than the hyperglycemic limit (in mg/dL) and less than
or equal to the hypoglycemic limit (in mg/dL) will be con-
sidered hyper- or hypoglycemic, respectively.
Time hyperglycemic/hypoglycemic. Total time (in h)
spent in the hyper- or hypoglycemic condition was estimated.
A linear model was used to approximate the time spent in the
hyper-/hypoglycemic ranges during the threshold crossing.
Glycemic time is expressed both in hours and as a percentage
of the total CGM period.
Time spent in each bin. The total time (in h) spent in each
bin (as defined above in ‘‘Bin thresholds’’) was estimated.
Table 1. Integrated Glycemic Variability Assessment for Patients with Diabetes
and Controls Without Diabetes
Metric
Subject
1
Subject
2
Subject
3
Subject
4
T1DM
group mean
Mean of controls
without diabetes*
Fold
difference
Mean glucose (mg/dL) 173.6 229.8 121.9 144.1 167 – 47 96.84 1.7
SD 80.8 90.1 55.2 69.5 74 – 15 14.13 5.3
MODD 107.8 100.0 57.5 54.3 80 – 28 14.41 5.6
CONGA(1) 60.4 54.5 35.7 41.9 48 – 11 12.91 3.7
CONGA(2) 87.1 80.9 54.8 64.1 72 – 15 15.89 4.5
CONGA(4) 111.1 114.6 71.5 87.5 96 – 20 18.26 5.3
MAGE 171.8 155.3 90.1 117.6 134 – 37 32.14 4.2
Time (%)
Hyperglycemic 39.7 68.9 15.6 23.2 37 – 24 0 —
Hypoglycemic 4.8 3.8 22.0 10.0 10 – 8 1.70 1.6
AUC (mg ·min/dL)/day
Hyperglycemic 43,813 96,761 7,050 23,425 (4.3 – 3.9) · 104
Hypoglycemic 726 911 5,356 2,071 2,265– 2,144
Percentage of time spent in each bin (%)
< 50mg/dL 1.0 1.5 9.7 3.3 4 – 4
50–70mg/dL 4.3 3.6 12.4 7 7 – 4
70–180mg/dL 60.8 36 62.3 68.6 57 – 14
180–220mg/dL 14.7 21 10.6 6.9 13 – 6
220–300mg/dL 19.1 37.7 5.1 15 19 – 13
Metric calculations are shown for patients with type 1 diabetes mellitus (T1DM) versus average reference values from subjects without
diabetes. Reference values from subjects without diabetes for mean glucose, percentage of time hyperglycemic, and percentage of time
hypoglycemic were obtained from the study of McDonnell et al.6 on 10 healthy controls.
*A twofold lower hypoglycemic percentage (1.7%) has been more recently reported in a study by the Juvenile Diabetes Research
Foundation Continuous Glucose Monitoring Study Group using 74 healthy controls without diabetes.12 Reference values from subjects
without diabetes for the remaining metrics were obtained from the study of Cameron et al.11 on 12 healthy controls without diabetes.
AUC, area under the curve; CONGA, continuous overall net glycemic action (number in parentheses represents h); MAGE, mean
amplitude of glycemic excursions; MODD, mean of daily differences.
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FIG. 1. Transition density profile: a cumulative measure of severity and frequency of glycemic change. (A) Raw continuous
glucose monitoring data from a diabetes patient with mean glucose equal to 121.9mg/dL. Colored horizontal bands indicate
different user-defined glucose ranges. (B) Raw continuous glucose monitoring data are categorized into bins according to
user-defined threshold ranges, defined here as (0, 50, 70, 180, 220, 300mg/dL). The percentage of time spent in each bin is
displayed in red. (C) Area under the curve above and below the hyper-/hypoglycemic limit of 180 (red) and 70 (blue) mg/dL,
respectively. The area under the curve is a measure of hyper- and hypoglycemic severity in conjunction with the (D)
transition speed, or the rate of change in glucose at the transition between each threshold. (Thresholds are defined as 0, 50, 70,
120, 180, 220, and 300mg/dL.) (Inset) Histogram of the slopes over each 5-min time interval. (E) Example of binned
continuous glucose monitoring data where a monotonic increase and decrease was observed. The duration of these mono-
tonic increases/decreases was then calculated for the (F) transition density profile. The number of transitions per day where
transitions are described as the magnitude of every continuous monotonic change in blood glucose levels, after smoothing,
sorted into the number of thresholds crossed (e.g., 2, 4, - 3, - 5) and separated into the time interval necessary to complete
each change (e.g., <1 h, between 1 and 2h, 2 and 3h, etc.). Negative numbers indicate monotonic decreases. Color graphics
available online at www.liebertonline.com/dia
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Mean glucose. Mean glucose (inmg/dL) is the arithmetic
mean of all raw CGM glucose values.
SD. The sample SD of all raw CGM glucose values was
taken.
MODD. MODD is the mean of all valid absolute value
differences between glucose concentrations measured at the
same time of day on two consecutive days (Table 2).
CONGA(n). CONGA(n) represents the SD of all valid
differences between a current observation and an observation
(n) hours earlier (Table 2).
MAGE. MAGE is calculated as the arithmetic average of
absolute value differences between adjacent glucose peaks
and nadirs, where the differences exceed 1 SD from the mean.
The algorithm was described by Fritzsche et al.13
Area under the curve. The area under the curve is the
graphical representation of two sets of cumulative areas un-
der the curve—a hyperglycemic set and a hypoglycemic set.
The areas were computed using a trapezoidal numerical in-
tegration function.
Input data plot. The input data plot is the line plot of the
raw CGM data. The horizontal lines indicate the user-defined
glycemic thresholds (Fig. 1A and B).
Transition speed. CGM-GUIDE provides two assess-
ments of the slopes of a patient’s CGM data: (1) a newly
developed scatter plot of slopes at transition points (Fig. 1C)
and (2) a histogram of the distribution of slopes between
every recorded time interval (Fig. 1D). The histogram pre-
sents the distribution of slopes between every two consec-
utive glucose measurements in the patient CGM data; the SD
of the slope is also calculated as a potential indicator of the
rate of glucose fluctuations. The scatter plot displays the
slopes of points flanking transitions from one user-defined
threshold into another (as described in ‘‘Transition density
profile’’).
Transition density profile. First, raw CGM data are par-
titioned into bins based on user-defined threshold values, and
exact transition points are established (Fig. 1B). Second, the
magnitude of every continuous monotonic change in glucose
levels, after smoothing, is sorted into the number of thresh-
olds crossed (e.g., 2, 4, - 3, - 5); negative numbers indicate
monotonic decreases, and positive numbers indicate mono-
tonic increases in glucose levels (Fig. 1E). Third, transitions are
separated into the time interval necessary to complete each
change (i.e., < 1 h, between 1 and 2 h, 2 and 3h, etc.). Finally,
the frequency of eachmonotonic threshold crossing per day is
plotted against the time interval needed to cross the indicated
number of thresholds (Fig. 1F). Gaps or null data points are
recorded, and the appropriate times are added to the corre-
sponding threshold transitions.
Safeguards and compatibility
The data collection time interval entered by the user is
checked against published statistical limits within which
variability metrics can be accurately assessed. When an in-
terval exceeds limits, an error message states, ‘‘Data collected
at intervals greater than 1 hour affect the accuracy of MAGE,
and intervals greater than 2–4 h affect the accuracy of SD and
CONGA(n) where n = 1, 2, or 4.’’15 Additionally, CGM-
GUIDE (Fig. 2) utilizes basic Excel data files, of glucose
readings only, as inputs. Output files from all available CGM
monitors are convertible to this format.
Table 2. Standard Measures of Glucose Variability
Name Formula Description Reference
Mean +
tn
t¼ t1
BGt
n
n =number of observations (number of glucose
readings for a given individual)
SD
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
+
tn
t¼ t1
(BGti  BG)
2
n 1
s
BG =mean glucose reading
n =number of observations
MODD
+
tk
t¼ t1
BGt  BGt 1440
k
k =number of observations where there is an
observation at the same time 24 h (1,440min) ago Molnar et al.5
CONGA(n)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
+
tk
t¼ t1
(Dt D)2
k 1
s
k =number of observations where there
is an observation n · 60min ago McDonnell et al.6
where Dt =BGt-BGt -m m = n · 60
and D¼
+
tk
t¼ t1
Dt
k
MAGE +k
x
k= the absolute value difference between
sequential glucose peaks and nadirs
Fritzsche et al.13
if k > v x=number of valid observations Baghurst14
v= 1 SD of mean glucose Service et al.4
BG, glucose reading at time t min after start of observations; CONGA(n), continuous overall net glycemic action (h); MAGE, mean
amplitude of glycemic excursions; MODD, mean of daily differences; ti, time (in min) after start of observations when the i
th observation is
taken.
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Results
Mean, SD, and time in glycemic states
To highlight the methodology behind the integrated gly-
cemic variability assessment, we provide information on a
group of four T1DM patients, in different strata of mean
glucose (below 125mg/dL, between 125 and 150mg/dL,
between 150 and 200mg/dL, and above 200mg/dL) that
capture the capability of the CGM-GUIDE. Data captured
with the CGM system show that the T1DM group had an
average mean glucose concentration of 167 – 47mg/dL,
which is a 72% increase above the average reference value for
control patients without diabetes (96.8mg/dL), and an aver-
age SD of 74– 15mg/dL, 5.3-fold higher than the average SD
of controls without diabetes (14.1mg/dL) (Table 1).
Because critical limits used to assess glucose control may
be heterogeneously standardized for different applications,
to accommodate for non-uniformity, we allow variable
thresholding of the CGM data and calculate the time spent
within each user-defined range. We chose threshold ranges
of (0–50; 50–70; 70–180; 180–220; and 220–300) and ob-
served all four patients within these ranges. For example,
Subject 3 was observed in each range 9.7%, 12.4%, 62.3%,
10.6%, and 5.1% of the time, respectively (Fig. 1B). To de-
termine if the lower mean glucose observed for Subject 3 is
reflective of good glycemic control, as measured by per-
centage of time out of normal glycemia, Subject 3 was ob-
served to experience hyperglycemia ( ‡ 180mg/dL) 15.6%
and hypoglycemia ( < 70mg/dL) 22.0% of the monitored
time compared with Subjects 1, 2, and 4, who experienced
hypoglycemia 4.8%, 3.8%, and 10%, respectively, and hy-
perglycemia 39.7%, 68.9%, and 23.3%, respectively. This
suggests Subject 3’s lower mean glucose reflects a higher
incidence of hypoglycemia and not necessarily better
FIG. 2. The CGM-GUIDE Interface. CGM-GUIDE allows for user-defined input of the threshold ranges, the hyper- and
hypoglycemic limits, and the continuous overall net glycemic action (CONGA) ‘‘n’’ value. Glucose variability metrics [SD,
MODD, CONGA(n), and mean amplitude of glycemic excursions (MAGE)] are calculated as described in Materials and
Methods in conjunction with glycemic statistics (time spent within thresholds, time spent in hyperglycemic/hypoglycemic
conditions, area under the curve, and mean glucose). Displays for area under the curve, transition speed, and slope histogram
plots (Fig. 1C and D) are available through a plot menu option. Color graphics available online at www.liebertonline.com/dia
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glucose control compared with Subjects 1, 2, and 4. The
controls without diabetes never reached the hyperglycemic
threshold and spent an average of 1.7% of the time below
the hypoglycemic limit (Table 1).
MODD, CONGA(n), and MAGE
As a measure of inter-day glucose variation, we calculated
the mean absolute value of daily differences (MODD) be-
tween glucose concentrations (Table 2). In the T1DM group,
the average daily variation was 80 – 28mg/dL, compared
with an averageMODD value of 14.4mg/dL in those without
diabetes. Because of inter-day comparisons, MODD is de-
pendent on patients’ adherence to a regular meal and insulin
schedule. Clinical experience has indicated that CGM traces
with high MODD values can be indicative of irregular habits
and thus require detailed contemporaneous lifestyle infor-
mation prior to interpretation (Table 1).6
As a supplement to MODD, we analyzed the differences in
glucose over a fixed interval using CONGA(n), which calculates
the SD of glucose differences n h apart. Because of the flexibility
of CONGA(n), we can assess time increments shorter than 24h
to provide a measure of intra-day glycemic variation and re-
duce dependence on the rigorous tracking of patient habits.
CONGA(1), CONGA(2), and CONGA(4) for the T1DM group
were found to be 48–11, 72–15, and 96–20mg/dL, respec-
tively. These values are four- to fivefold greater than the corre-
sponding mean control values in those without diabetes of 12.9,
15.9, and 18.3mg/dL, respectively (Table 1). For healthy con-
trols, the time period, n, used to calculate CONGA has minimal
effect on the metric value. For patients with diabetes, how-
ever, CONGA(n) values have been shown to increase with n
(1 to 8hours), gradually leveling off as n approaches 4h.11
MAGE considers adjacent glucose peaks and nadirs whose
absolute differences exceed 1 SD from the mean and calculates
the arithmetic average of these differences. T1DMpatientswith
brittle glucose concentrations are therefore expected to have
higher MAGE values than normal, healthy individuals. Cor-
respondingly, the T1DM group was found to have a MAGE
value of 134– 37mg/dL, fourfold greater than the average
MAGE of 32.1mg/dL found in healthy controls (Table 1).
Area under the curve, slope histogram, and transition
speed scatterplot
For a more visual interpretation of glucose control, we
calculated the area under the curve plots to depict the degree
of glucose deviation above or below glycemic limits.16 In the
T1DM group, the area above the hyperglycemic limit
(180mg/dL) was (4.3 – 3.9) · 104mg$min/dL, whereas the
area below the hypoglycemic limit (70mg/dL) was
(2.3 – 2.1) · 103mg$min/dL (Fig. 1C).
We next assessed the glucose rates of change as a direct way
to quantify and analyze the severity of fluctuations in glucose
levels. CGM-GUIDE calculates the rate of change between
every two consecutive CGM measurements and then consoli-
dates all the slopes and presents them in a histogram (Fig. 1D,
inset). The SD of the slope distribution is representative of the
dispersion in speed of glucose changes and was measured as
1.2mg/(dL$min) for the subject with the lowest mean glucose
level, Subject 3 (Fig. 1D, inset). It is notable that this SDof slopes
is distinct from the SD measured previously, which is a mea-
surement of the variation in glucose concentrations.
To differentiate from slope histogram, which displays glu-
cose rates of change calculated at every sampling point, we also
assessed the transition speed scatterplot that focuses on glucose
dynamics during threshold crossings. CGM-GUIDE calculates
the glucose rate of change across each threshold intersection
and then plots the slope against the intersection time (Fig. 1D).
Expressing these ‘‘transition speeds’’ in a graphical manner al-
lows for ready visualization of dangerous glucose excursions
and for early detection of potentially severe hyper- or hypo-
glycemia that could be addressed by adjusting insulin therapy.
Subject 3 experienced fast transitions across thresholds, with an
absolute value above 4, in 7.8% of transitions crossed (Fig. 1D).
Transition density profiles
Wedeveloped a novel transition density profile that reports
the frequency, relative magnitude, and time taken for glucose
levels to cross user-defined thresholds. Transition density
profiles permit easy assessment of glucose dynamics across
critical thresholds of glycemia (for calculation, see Materials
and Methods). Subject 3’s transition density profile depicted
multiple large monotonic changes in glucose values (Fig. 1F).
Large changes occurring over shorter timeframes are
assumed to cause greater stress to the body than similar
transitions occurring over longer timeframes. For example,
the ( - 2 level) transitions that required between 1 and 2 h to
complete would not cause the same level of stress as the more
rapid (- 2 level) transitions observed in less than 1 h (Fig. 1F).
Discussion
We present here a clinician-friendly CGM-GUIDE that si-
multaneously calculates statistics, including mean glucose
and (percentage) time spent in hyperglycemic and hypogly-
cemic conditions, alongwith data thresholding based on user-
specified glucose ranges. Thresholding allows for any range
of glucose concentrations to be independently assessed for
time spent in these ranges and for transition speeds between
ranges to be estimated. Uniquely, CGM-GUIDE calculates the
most widely used glucose variability metrics—SD, MODD,
CONGA(n), and MAGE—and presents them visually all in
one setting, like a dashboard. Data from the most popular
CGM collection monitors and software systems including the
Freestyle Navigator CoPilot Health Management System
(Abbott, Abbott Park, IL), CareLink Personal Therapy
Management (Medtronic), MiniMed solutions pumps (Med-
tronic), and DexCom Data Manager 3 SEVEN PLUS
(DexCom, San Diego, CA) can be adapted for use with CGM-
GUIDE. The aggregated format provides a more complete
picture of glycemic control while facilitating comparisons
between glucose variability and various insulin algorithms
for the potential design of more accurate insulin adjustments.
Additionally, CGM-GUIDE provides interactive graphical
representations of CGM data, including (1) raw data with a
display of user-defined threshold ranges, (2) area under the
curve above or below user-defined hyper- and hypoglycemic
limits, (3) a new graph of transition speeds across user-
defined thresholds, (4) a histogram of slopes, and (5) a novel
histogram plot—the transition density profile—indicating the
magnitude and frequency ofmonotonic increases or decreases
in the glucose data, over the time duration necessary for
transitions to occur.
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Continuous glucose monitors have afforded patients and
physicians the flexibility to track glucose trends throughout
the day, to assess individualized response to exercise and
various stressors, and to evaluate nocturnal glucose trends,
including frequency and trends of hypoglycemia. As the use
of continuous glucose monitors increases, conclusions previ-
ously drawn from finger prick profiles can be tested against
this more robust dataset and used to guide optimization in
individualized insulin regimens and effective prevention of
severe hypo- and hyperglycemia. Ultimately, data obtained
with this tool may be used to assess the relationship with
chronic diabetes complications and disease progression in
either future long-term prospective clinical studies and/or
with data previously collected during former follow-up
studies. Cameron et al.11 compared the performance of many
of the metrics listed above and identified inherent properties
and applications associated with each metric. Some of the
metrics, such as average daily risk range, are more appro-
priate for routine self-monitored blood glucose data,9 whereas
CONGA(n) was designed specifically for CGM data.17 Apart
from the necessity of differentiating between methods for
analyzing self-monitored blood glucose versus CGM read-
ings, many investigators acknowledge the subjectivity of
certain extant glucose variability metrics. For example, re-
searchers have criticized the M-value andMAGE—two of the
earliest glucose variability measurements formulated—for
their reliance on glucose reference points and subjective def-
initions for glycemic peaks and nadirs.17 Nonetheless, MAGE
is still one of the most commonly used metrics for describing
glucose variability in diabetes studies. Only as of 2011 did a
standardized computer algorithm become available for the
calculation of MAGE.13,14
Rapid variability in glycemia has been thought to incor-
porate additional ‘‘stress’’ to a patient’s system and has been
reported to induce increased oxidative stress,1 and these in
concert were proposed to contribute to the development of
microvascular complications.2,3 There exist, however, con-
flicting conclusions on the relationship between glucose var-
iability and these aforementioned complications.3,18 For
example, some statistical models developed using the gly-
cemic profile data collected during the landmark Diabetes
Control and Complications Trial (DCCT) suggested a rela-
tionship between fluctuations in glucose and the development
of retinopathy, nephropathy, and neuropathy.19 However,
recent independent analyses of DCCT glycemia data per-
formed by the DCCT coordinating center have contradicted
these findings and reported that the SD of glucose does not
relate to the progression of microvascular complications in
general.20,21 Similarly, Siegelaar et al.21 used SD andMAGE to
evaluate the relationship between DCCT glucose data and
complications, concluding that glucose variability as assessed
by these measures does not contribute to the development of
peripheral and autonomic neuropathy.
The inconsistent results on the relationship between some
measures of glucose dynamics and the development of spe-
cific diabetes complications reported by these investigators
may be, however, due to the insensitivity of glucose data as
obtained from only five- to seven-point single monitor glu-
cose profiles in accurately assessing glucose variability. These
discretemeasures of glucose provide only limited information
on a patient’s glucose dynamics over a 24-h period compared
with the study of CGM data. In addition, as discussed earlier,
statistical measurements of SD do not provide a comprehen-
sive assessment of glucose variability, especially when the
dataset contains a relatively sparse set of glucose measure-
ments. In particular, recent work suggests the calculations of
SD and CONGA(4) become unreliable when data measure-
ments are taken more than 2–4 h apart, whereas MAGE be-
comes unreliable at observation intervals >1 h.15
Furthermore, different measures of glucose variability may
be appropriate for assessing different physiological condi-
tions. Many studies that use an individual metric in isolation
to correlate glucose variability with clinical complications
may observe correlations but are not complete in their as-
sessment of variability. Cameron et al.11 demonstrated that
glucose variability metrics, although correlated with each
other in patients without diabetes, are not correlated in pop-
ulations with diabetes. Thus, studies in populations with di-
abetes that look at only one or two measures of glucose
variability are somewhat misleading because they do not take
into account the range of available glycemic metrics.22–24
In contrast to (analyses of) diabetes patients, analyses of
critically ill adult and pediatric intensive care unit patients
without diabetes have indicated correlations between glucose
variability and mortality regardless of illness or severity.18
Glucose variability, as measured by SD, has been shown to be
a significant predictor of mortality in the adult intensive care
unit by three independent groups25–27 and in two different
pediatric intensive care units,28,29 suggesting a need for glu-
cose control in patients without diabetes. These findings,
along with the observation that mortality was observed to
significantly increase with glucose variability in different
strata of mean glucose levels,27 suggest that glucose variability
is a predictor of mortality independent from mean glucose
level. Consequently, the calculation andmonitoring of glucose
variability would be of added importance for the general care
of adult and pediatric patients in intensive care units.
In summary, the development of CGM-GUIDE provides
researchers and clinicians with an easy-to-use tool for a supe-
rior assessment of a patient’s glucose landscape. The interface
calculates and displays multiple metrics from CGM data, of-
fering not only a multifaceted approach to studying glucose
variability, but also a means to investigate glucose variability
using more information-rich datasets. CGM-GUIDE will be
made publicly available as a web-based application, similar to
other recent glycemic calculators,30 and will provide enhanced
graphic and user-defined options. Clinicians initiating CGM
use in their practice will also have the option to request ad-
vanced education and training classes in usingCGM-GUIDE to
open discussion about glucose variability as continued snap-
shots of patient progress over time. By combining metrics into
an aggregate tool, we anticipate the use of integrated glycemic
variability assessments to guide clinicians in designing better
insulin delivery algorithms for patients with T1DM and po-
tentially supplement the current use of hemoglobin A1c in the
global assessments of the relationship between glucose vari-
ability and the development of diabetes complications.
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